211 results
424B3
QLGN
Qualigen Therapeutics Inc
3 May 24
Prospectus supplement
1:50pm
in women; it accounts for about 3% of all cancers in the United States but is responsible for about 8% of all cancer-related deaths. It has one of the lowest … responsible to pay on our behalf our in-license royalty obligations to ULRF, as and when required.
Finally, if the contemplated closing had occurred
POS AM
QLGN
Qualigen Therapeutics Inc
30 Apr 24
Prospectus update (post-effective amendment)
6:58pm
in the United States but is responsible for about 8% of all cancer-related deaths. It has one of the lowest rates of survival of all cancer types … would have paid us an upfront fee of $1,000,000 in cash. In addition, Pan-RAS Holdings would have become responsible to pay on our behalf our in-license
8-K
EX-10.3
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
8-K
EX-10.4
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
agree that, notwithstanding anything in this Agreement to the contrary, in no event shall either Party be responsible or liable in connection
8-K
jmts5y3gy ljktmjc44
28 Mar 24
Termination of a Material Definitive Agreement
4:05pm
8-K
EX-10.1
aw17f51otkg8v3u2 44s
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.3
rsj68os
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
4um3k05k
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.1
l99epx g65sj
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-10.1
uynudvfh9bw
7 Dec 23
Entry into a Material Definitive Agreement
4:15pm